Effects of the Novel Acetylcholinesterase InhibitorN-Octyl-1,2,3,4-tetrahydro-9-aminoacridine on Locomotor Activity and Avoidance Learning in Mice

The acetylcholinesterase reversible inhibitor N-octyl-1,2,3, 4-tetrahydro-9-aminoacridine (THA-C8) is a new synthesized derivative of tacrine (THA) characterized by an alkyl chain in the molecular structure which ameliorates the penetrability of the compound into the central nervous system. THA-C8 (0.1-5 mg/kg) significantly reduced spontaneous locomotor activity in CD1 mice at a dose of 3 mg/kg. Moreover, THA-C8 (0.2-2 mg/kg) significantly improved shuttle-box avoidance acquisition at doses (0.25, 0.3, 1 mg/kg) not affecting locomotion and that are much lower than the doses reported to be effective for THA in animal models. From the data reported it seems that the new compound could be interesting for therapeutic purposes.

[1]  F. Pavone,et al.  Shuttle-Box Avoidance Learning in Mice: Improvement by Combined Glucose and Tacrine , 1998, Neurobiology of Learning and Memory.

[2]  M. Pomponi,et al.  Studies on a new series of THA analogues: Effects of the aromatic residues that line the gorge of AChE , 1997, FEBS letters.

[3]  Gastone G. Celesia,et al.  A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease , 1994 .

[4]  Anthony F Jorm,et al.  Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial , 1994, BMJ.

[5]  A. Adem.  The next generation of cholinesterase inhibitors , 1993, Acta neurologica Scandinavica. Supplementum.

[6]  Martin R. Farlow,et al.  A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. , 1992, JAMA.

[7]  R F Woolson,et al.  A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. , 1992, The New England journal of medicine.

[8]  S. E. Freeman,et al.  Tacrine: A pharmacological review , 1991, Progress in Neurobiology.

[9]  G. Dawson,et al.  The behavioral effects of heptyl physostigmine, a new cholinesterase inhibitor, in tests of long-term and working memory in rodents , 1991, Pharmacology Biochemistry and Behavior.

[10]  J. Sirviö,et al.  Effects of THA on passive avoidance retention performance of intact, nucleus basalis, frontal cortex and nucleus basalis + frontal cortex-lesioned rats , 1991, Pharmacology Biochemistry and Behavior.

[11]  S. Asai,et al.  Effect of 9-amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta-(b)-quinoline monohydrate hydrochloride (NIK-247) on cholinergic enzyme activity in rats , 1991, Pharmacology Biochemistry and Behavior.

[12]  J. Sirviö,et al.  Tetrahydroaminoacridine alleviates medial septal lesion-induced and age-related spatial reference but not working memory deficits , 1991, Physiology and Behavior.

[13]  S. Iversen,et al.  Direct comparison of cognitive facilitation by physostigmine and tetrahydroaminoacridine in two primate models , 1990, Neurobiology of Aging.

[14]  G. Chatellier,et al.  Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine. , 1990, BMJ.

[15]  A. Hunter,et al.  The cholinergic pharmacology of tetrahydroaminoacridine in vivo and in vitro , 1989, British journal of pharmacology.

[16]  J. Flood,et al.  Effect of acute arecoline, tacrine and arecoline + tacrine post-training administration on retention in old mice , 1988, Neurobiology of Aging.

[17]  M. Pomponi,et al.  A long-lasting cholinesterase inhibitor affecting neural and behavioral processes , 1987, Pharmacology Biochemistry and Behavior.

[18]  R. Lévy.  TETRAHYDROAMINOACRIDINE AND ALZHEIMER'S DISEASE , 1987, The Lancet.

[19]  A. Kling,et al.  Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. , 1986, The New England journal of medicine.

[20]  R. Bartus,et al.  The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.

[21]  V. Libri,et al.  Effects of oxiracetam-scopolamine combinations on shuttle-box avoidance acquisition in mice. , 1988, Archives internationales de pharmacodynamie et de therapie.

[22]  M. Pomponi,et al.  New analogs of physostigmine: alternative drugs for Alzheimer's disease? , 1988, Life sciences.